A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

This Phase II trial tests a targeted antibody-drug therapy called SHR-A1811 in women with recurrent or metastatic cervical cancer whose tumors express HER2 — a protein found on the surface of some cancer cells. The drug is designed to deliver chemotherapy directly to cancer cells. **You may be eligible if:** - You are a woman between 18 and 75 years old with pathology-confirmed cervical cancer - Your cancer has come back or spread and you have received prior treatment - You have adequate organ function (blood counts, kidney, liver, heart) - Your expected survival is at least 12 weeks - You agree to use effective contraception and are not breastfeeding **You may NOT be eligible if:** - You have untreated or active brain metastases - You have had another type of cancer - You have uncontrolled fluid around the lungs or heart - You have a history of interstitial lung disease or serious lung inflammation - You have poorly controlled heart disease or recent blood clots - You have had a serious infection within the past month - You have a history of HIV or immunodeficiency Talk to your doctor to see if this trial is right for you.